Healthcare Industry News: dilatation catheter
News Release - June 7, 2007
New Balloon Catheter Available Worldwide for Carotid and Renal Angioplasty ProceduresAVIATOR(TM) Plus Balloon dilatation catheter Rapid Exchange Facilitates Procedural Speed and Efficiency
BALTIMORE, June 7 (HSMN NewsFeed) -- Today at the 61st Annual Meeting of the Society for Vascular Surgery, Cordis Endovascular, division of Cordis Corporation, announced the worldwide launch of the Cordis AVIATOR(TM) Plus Balloon dilatation catheter for use in angioplasty procedures for patients with carotid and or renal artery blockages. AVIATOR(TM) Plus combines a unique high-pressure expansion and low profile .014 inch rapid exchange (RX) or single operator system that facilitates procedural speed and efficiency by enabling fast inflation and deflation times. Fast inflation and deflation time during carotid or renal intervention procedures helps to limit the period of distal ischemia, and the low profile may help reduce the risk of plaque disruption and embolization when crossing the lesion.
The AVIATOR(TM) Plus draws on the innovative delivery technology of the AVIATOR(TM) Catheter, first launched by Cordis Endovascular in the United States in 2002. As with other Cordis Endovascular percutaneous transluminal angioplasty (PTA) catheters, the AVIATOR(TM) Plus gets its strength from Cordis' market leading DURALYNŽ Balloon Material which allows for precise and consistent inflation diameters.
"The AVIATOR(TM) Plus is one of only two carotid indicated PTA balloon dilatation catheters available and further supports Cordis Endovascular's continued commitment to providing leading technology for the treatment of carotid and renal artery disease," said Dennis Donohoe, M.D., Vice President, Worldwide Clinical and Medical Affairs, Cordis Corporation.
AVIATOR(TM) Plus features include a sleek (<.90mm) manicured tip, 3.3 french shaft, and modified DURALYNŽ Balloon Material on a 4 french system. It is available in 4 - 7mm diameters and 1.5 - 4cm lengths on 142cm shafts. More information on the AVIATOR(TM) Plus can be found on http://www.jnjgateway.com.
Cordis Endovascular is a recognized leader in endovascular research and development and is committed to serving the cardiology, radiology and vascular surgery communities through the development of groundbreaking technologies for the treatment of peripheral vascular disease. It constantly seeks solutions to the human anatomy's most challenging problems, such as carotid artery disease, superficial femoral artery disease, venous thrombotic disease, lower extremity disease and aortic aneurysm.
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsOver 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study
MedAlliance leads US Sirolimus DEB race: First US Patient enrolled into SELUTION SLR Coronary Sirolimus DEB Study
MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval